MAPT and Alzheimer disease: In a larger cohort, plasma P‐tau181 was shown to differentiate AD dementia from non‐AD dementia disorders with a somewhat higher AUC (0.94), similar to those achieved using CSF P‐tau181 or tau PET (Janelidze et al, 2020a).